Overview

A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's Disease

Status:
Completed
Trial end date:
2005-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to evaluate natalizumab in individuals with moderately to severely active Crohn's Disease.
Phase:
Phase 3
Details
Lead Sponsor:
Biogen
Collaborator:
Elan Pharmaceuticals
Treatments:
Natalizumab